



59 MDW/ST Summary of Funding Announcements for October 2020



- **SAN ANTONIO MEDICAL FOUNDATION GRANT GUIDELINES FOR COLLABORATING ENTITIES 2021 CYCLE**

PROGRAM OVERVIEW

The San Antonio Medical Foundation (SAMF) has established a collaborative grant program for encouraging healthcare and bioscience entities to use the funds as “seed money” incentives for new collaborative initiatives. The use of the funds is intended to explore new area(s) targeting special research and patient care strengths already present in the greater San Antonio area by those entities actually performing the research and patient care. It is the intent of the SAMF to be an “encourager” rather than an “investor”. Priority is given to the pre-identified areas of excellence (listed alphabetically) for our community of:

- Aging Studies
- Cancer
- Diabetes
- Infectious Diseases
- Neurologic Disorders; and
- Trauma/Wound Care/Regenerative Medicine.

Proposals should be submitted for exploratory or novel collaborative initiatives that break new ground or extend previous initiatives leading in a new direction or toward new and innovative approaches likely to raise the profile of leadership of the San Antonio community in healthcare innovation.

Proposals will be reviewed in light of the ability of the collaborative effort to leverage the strengths of each institution within the City of San Antonio to create a foundational collaboration or alliance which is likely to result in national or international preeminence or recognition.

ELIGIBILITY

The request may only be submitted by a not-for-profit or governmental entity; however, a participating partner may be a for-profit entity.

FUNDING SOURCE

Both the Infrastructure and Collaborative Grant programs are funded by utilizing up to five-percent (5%) of the balance of the Mission Related Investment Fund as of December 31st of the previous year.

FUNDING LIMITS

The maximum amount for an individual annual award will be \$200,000 and the duration of the grant will be one year. However, in *very exceptional* cases larger grants (maximum of \$200,000 per year for up to 4 years) may be entertained if proper justification is provided. It



59 MDW/ST Summary of Funding Announcements for October 2020



is anticipated that the initial grant performance period would be from the fourth quarter of each year for one year.

* The availability of funds and the absence of any adverse impact on long term resources of the Foundation must be verified by the SAMF Fund Board in all cases before any distribution may occur.

PROPOSAL SUBMISSION

A Notice of Intent (NOI) to apply must be submitted by December 15 of each year to pam@samedfoundation.org. In the NOI email, please provide the name and title for the Initiative Leader or leads on the initiative (each an Initiative Leader), with associated organizational affiliation. The NOI is just an indication that your initiative intends to apply, no specific details regarding the proposed project is needed at this time.

There will be one submission cycle with a deadline at the close of business (5:00 pm) on the last work day of March each year. Award funds will be available following the conclusion of the review process. The Initiative Leader will submit one combined proposal to Pam Leissner by email to pam@samedfoundation.org

All required proposal elements shall be contained in a single file with single spacing in Arial font, with font size 11 points. The proposal must include the following in order shown below:

1. Proposal Cover Page (Use Attachment A)
2. Project Description: 3 page maximum
3. Joint Execution Plan: 2 page maximum
4. Budget Summary (Use Attachment B)
5. Budget Justification: 1 page maximum per Initiative Leader
6. Biographical Sketch: 2 page maximum for each Initiative Leader

Notices of Intent simply need to state that you intend to submit an application and must be emailed to pam@samedfoundation.org no later than December 15, 2020.

- **Congressionally Directed Medical Research Programs (CDMRP);**
<https://cdmrp.army.mil/default> (to subscribe for email notifications when program announcements are released by CDMRP, consider subscribing under "Email Subscriptions" on the eBRAP homepage at <https://eBRAP.org>)

- **FY20 Rare Cancers Research Program (RCRP)**

Concept Award

<https://cdmrp.army.mil/funding/pa/FY20-RCRP-CA.pdf>

The CDMRP expects to allot approximately \$1.76M to fund approximately 11 Concept Award applications.

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), November 12, 2020 • Application Submission Deadline: 11:59 p.m. ET, November 30, 2020 • End of Application Verification Period: 5:00 p.m. ET, December 3, 2020 • Peer Review: January 2021 • Programmatic Review: March 2021



59 MDW/ST Summary of Funding Announcements for October 2020



Idea Development Award

<https://cdmrp.army.mil/funding/pa/FY20-RCRP-IDA.pdf>

The CDMRP expects to allot approximately \$2.80M to fund approximately five Idea Development Award applications.

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), November 12, 2020 • Application Submission Deadline: 11:59 p.m. ET, November 30, 2020 • End of Application Verification Period: 5:00 p.m. ET, December 3, 2020 • Peer Review: January 2021 • Programmatic Review: March 2021

Resource and Community Development Award

<https://cdmrp.army.mil/funding/rcrp>

The CDMRP expects to allot approximately \$1.92M to fund approximately two RCDA applications.

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), November 12, 2020 • Application Submission Deadline: 11:59 p.m. ET, November 30, 2020 • End of Application Verification Period: 5:00 p.m. ET, December 3, 2020 • Peer Review: January 2021 • Programmatic Review: March 2021

Reconstructive Transplant Research Program Clinical Network Award

<https://cdmrp.army.mil/funding/pa/FY20-RTRP-CNA.pdf>

The period of performance for Phase I is 2 years, with maximum funding of \$3 million (M) in total costs to the Coordinating Center. The Coordinating Center will manage funding to the Network Sites as subawards and for other key collaborators. RTRP funding for the Phase II option is contingent on successful completion of Phase I objectives and on available funding.

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), November 17, 2020
- Application Submission Deadline: 11:59 p.m. ET, December 3, 2020 • End of Application Verification Period: 5:00 p.m. ET, December 8, 2020 • Peer Review: January 2021 • Programmatic Review: March 2021
- **The Hearing Health Foundation (HHF)**'s next Emerging Research Grants (ERG) grant program provides seed money to researchers with innovative approaches to hearing and balance science. Grantees advance knowledge in the following under-researched areas, among others:
 - Hearing loss in children
 - Auditory processing disorder
 - Hyperacusis
 - Tinnitus
 - Ménière's disease
 - Usher syndrome
 - Reducing the ototoxicity of cancer drugs
 - Links between hearing loss and diabetes and heart and kidney disease



59 MDW/ST Summary of Funding Announcements for October 2020



<https://hearinghealth.foundationconnect.org/grantsmanager/Pages/V3/Portal/eligibilityquiz.aspx?OrgID=00D700000001qzZ&QuizID=a0h390000009CqGU&lang=en>

- **BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement**
<https://beta.sam.gov/opp/a93347912ee54559b9bbbd98106a0cd4/view>

- **NIH Funding Opportunities Specific to COVID-19**

Title	Notice Number	Organization(s)	Release Date	Expiration Date
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)	NOT-HL-20-814	NHLBI	15-Sep-20	6-Jul-24
Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	NOT-AI-20-065	NIAID	13-Aug-20	1-Sep-21
Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	NOT-MD-20-025	NIMHD, NCI, NIDA, NLM, ODP, OBSSR, NIMH, NIAMS	13-Aug-20	8-May-23
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)	RFA-TR-20-003	NCATS	5-Aug-20	24-Jan-21
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)	PAR-20-256	NIAID	13-Jul-20	8-Jul-21
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and	RFA-DK-20-021	NIDDK	10-Jul-20	17-Dec-20



59 MDW/ST Summary of Funding Announcements for October 2020



Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)				
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NOT-AI-20-059	NIAID	6-Jul-20	2-Jul-21
Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)	PAR-20-243	NIMH, NCCIH, SGMRO, ODP, NIDCD, OBSSR, NIEI, NIDA, NIA, NIAAA, NICHD, NCATS, ORWH, NIDCR, NINR, NIMHD	25-Jun-20	3-Mar-21
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project	NOT-OD-20-129	NIH, NCI, NHGRI, NCCIH, NINDS, ORIP, NIMHD, NIA, NIDCR, NIAID, NIAMS, NIEHS, NCATS, NIDCD, NICHD, NIDDK, NHLBI	25-Jun-20	13-Jul-21
Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)	PAR-20-237	NIMHD, NIDCD, NIMH, ODP, NINR, NIA, SGMRO, NIDDK, NIEHS, NICHD, NCATS, ORWH, NIAAA, NCCIH, NIDA, NIEI, NIDCR	17-Jun-20	2-Dec-20
Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Health Need	NOT-TR-20-029	NCATS	15-Jun-20	11-Nov-20



59 MDW/ST Summary of Funding Announcements for October 2020



NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)	PAR-20-234	NIA	15-Jun-20	2-Feb-21
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations	NOT-MD-20-022	NIMHD, NIAAA, NCCIH, NIDCR, NCATS, NIEHS, ORWH, NIDA, OBSSR, NIDCD, SGMRO, NICHD, ODP, NIMH, NHLBI, NIA, NEI, NIDDK	5-Jun-20	30-Dec-20
Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19	NOT-MH-20-053	NIMH, NICHD, ORWH, NIDCR, NCATS, NIDA, OBSSR, NCCIH, NINR, ODP, NIDCD, NHLBI, NIA, NEI, NIAAA, NIMHD, SGMRO, NIDDK	5-Jun-20	30-Dec-20
Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders	NOT-DC-20-008	NIDCD	4-Jun-20	8-Sep-22
Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NOT-AI-20-051	NIAID	19-May-20	8-Sep-21
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR	NOT-DE-20-022	NIDCR, ORWH	5-May-20	3-Nov-20



59 MDW/ST Summary of Funding Announcements for October 2020



Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network	NOT-DE-20-023	NIDCR	1-May-20	3-Nov-20
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System	NOT-NS-20-051	NINDS	30-Apr-20	15-Apr-21
Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs	NOT-TR-20-028	NCATS	23-Apr-20	11-Nov-20
Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA	NOT-AA-20-011	NIAAA	16-Apr-20	16-Apr-21
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences	NOT-OD-20-097	OBSSR , NCCIH , NCI , NHGRI , NHLBI , NIA , NIAA , NICHD , NIDDK , NIEHS , NINR , ODP , ORWH	13-Apr-20	1-Apr-21



59 MDW/ST Summary of Funding Announcements for October 2020



Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	NOT-ES-20-020	NIEHS	10-Apr-20	4-May-21
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities	NOT-MD-20-019	NIMHD, NIA, NIAAA, NIMH, ODP	9-Apr-20	1-May-21
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus	NOT-TR-20-017	NCATS	9-Apr-20	26-Jan-22
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus	NOT-MH-20-047	NIMH, NIA, ODP, NIAAA, NIMHD	9-Apr-20	16-Apr-21
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus	NOT-TR-20-016	NCATS	9-Apr-20	26-Jan-22
Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	NOT-ES-20-015	NIEHS	8-Apr-20	4-May-21



59 MDW/ST Summary of Funding Announcements for October 2020



Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	NOT-AG-20-022	NIA, NIMH	2-Apr-20	1-May-21
RESCINDED - Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NOT-AI-20-031	NIAID	27-Mar-20	5-Apr-21
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2	NOT-GM-20-025	NIGMS	25-Mar-20	6-Feb-21
Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need	NOT-TR-20-011	NCATS	24-Mar-20	10-Jul-21
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	NOT-DA-20-047	NIDA	19-Mar-20	31-Mar-21
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	PA-20-135	NIH, NCATS, NCCIH, NCI, NHGRI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINR, NLM, ORWH, OSC	10-Mar-20	8-Sep-25



59 MDW/ST Summary of Funding Announcements for October 2020



- **NIH: Notice of Special Interest in Physiological Monitoring and Point of Care Technologies for Trauma Care** <https://grants.nih.gov/grants/guide/notice-files/NOT-EB-19-018.html>

Notice Number: NOT-EB-19-018

Key Dates

Release Date: August 29, 2019

First Available Due Date: October 5, 2019

Expiration Date: January 8, 2022

Related Announcements

PA-18-418 "NIBIB Research Project Grant (R01 Clinical Trial Required)"

PA-19-056 "NIH Project Grant (Parent R01 Clinical Trial Not Allowed)"

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing physiological sensors for application in trauma care.

Background

Trauma care focuses on the critical time immediately after an injury or acute shock, in an event that may affect one person or many. Termed "the golden hour," the exact window of time depends on many variables, including the patient's underlying health, the nature of the traumatic occurrence, the scale of casualties, and the equipment and expertise at hand. The trauma environment is constantly changing due to ongoing injury, the possible involvement of multiple tissue types, modulation by the immune system, and/or infection. To broadly address trauma care the National Institute of Biomedical Imaging and Bioengineering (NIBIB), Uniformed Services University of the Health Sciences (USUHS), and Food and Drug Administration (FDA) cosponsored a workshop on March 21–22, 2019 to link the needs of the Department of Health and Human Services and the Department of Defense with nascent bioimaging and bioengineering solutions. Among the biotechnological gaps identified at the meeting, biological monitoring devices that can be deployed outside of the hospital setting, including use of devices well beyond a literal hour of time before reaching a hospital, are sought to address the complex spectrum of needs. Additionally, a high priority across technologies and settings are novel approaches to effectively collecting, accessing, and using data associated with trauma care.

Research Objectives

This Notice invites research projects that seek to fill gaps in trauma care such as rapid triage and accurate risk assessment through the development of physiological monitors, biochemical agent detectors, and point of care technologies capable of operating in dynamic environments. Applications should involve expertise across multiple disciplines as relevant to the proposed research. Applications can address different technology development stages, from early technology development to testing in animal models and human subject research. Projects focused on the development of sensing modalities



59 MDW/ST Summary of Funding Announcements for October 2020



should prioritize wearable and minimally invasive sensors (e.g. microneedle patches). Projects proposing to integrate sensors into armbands / wrist watches or enable the sensor readout through a smartphone application are not appropriate for this Notice.

National Institute of Biomedical Imaging and Bioengineering Statement of Interest (NIBIB):

The NIBIB is interested in projects focused on developing new acquisition and interpretation hardware and software for non-invasive and minimally invasive physiological monitors (e.g. microneedle patches), diagnostic, and therapeutic techniques to be used in the dynamic trauma environment. Topics identified as high interest include, but are not limited to, the following:

- Advance algorithm and deep learning techniques for continuous analysis and interpretation of multiple physiological data streams from multiplexed sensors
- Sensors for noninvasive or minimally invasive measurement of relevant biochemical markers and vital signs (e.g. O₂ saturation), pathogens, biochemical agents, or hormones in biofluids (e.g. sweat, saliva, interstitial fluid)
- Rapid toxicology screening systems
- Small, portable, rugged devices capable of autonomous operation, utilizing flexible materials for improved wearability and ease of operation, and offering optical or sound-based readout options
- Closed loop electrocardiogram systems with digital health readouts
- Portable technologies utilizing sensor arrays for pulmonary disease diagnostics
- Technologies for wound diagnostics

Application and Submission Information:

This Notice applies to due dates on or after October 5, 2019 and subsequent receipt dates through January 8, 2022.

Applications for this Notice must submit an application through NIH Parent Announcement PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) or, if you are proposing a clinical trial, to PA-18-418: NIBIB Research Project Grant (Parent R01 Clinical Trial Required). Note that applications to PA-18-418 should propose early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

- For funding consideration, applicants must include "NOT-EB-19-018" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.



59 MDW/ST Summary of Funding Announcements for October 2020



Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

Šeila Selimovic, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-4577
Email: seila.selimovic@nih.gov

Tiffani Bailey Lash, Ph.D. (Point of Care Technologies)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-471-4778
Email: tiffani.lash@nih.gov

- **Ecology and Evolution of Infectious Diseases (EEID)**

Synopsis of Program:

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.



59 MDW/ST Summary of Funding Announcements for October 2020



Cognizant Program Officer(s):

Please note that the following information is current at the time of publishing. See program website for any updates to the points of contact.

- Katharina Dittmar, Program Director, NSF/BIO, telephone: (703) 292-7799, email: kdittmar@nsf.gov
- Christine Jessup, Program Director, NIH/FIC, telephone: (301) 496-1653, fax: (301) 402-0779, email: christine.jessup@nih.gov
- Mark Mirando, National Program Leader, USDA/NIFA, telephone: (202) 445-5575, email: mark.mirando@usda.gov
- Iain Templeman, Portfolio Manager, UKRI/BBSRC, telephone: 44(0)1 793-413 368, email: iain.templeman@bbsrc.ukri.org
- Rachel (Henri) Haring, Deputy Executive Director, BSF, telephone: 972 2 5828239, email: heni@bsf.org.il
- Xiuping Liu, Division Director, NSFC, telephone: 86 10-62325377, email: liuxp@nsfc.gov.cn
- Daniel Janes, Program Director, NIH/NIGMS, telephone: (301) 594-0943, email: daniel.janes@nih.gov
- Stephanie Coomes, Health Scientist Administrator, NIH/NIAID, telephone: (301) 761-6855, email: stephanie.coomes@nih.gov
- Jing Chen, Program Manager, NSFC, telephone: 86 10-62326877, email: chenjing@nsfc.gov.cn
- Rebecca Ferrell, Program Director, NSF/SBE, telephone: (703) 292-7850, email: rferrell@nsf.gov
- Siobhan M. Mattison, NSF/SBE, telephone: (703) 292-2967, email: smattiso@nsf.gov
- Daniel J. Thornhill, Program Director, NSF/GEO, telephone: (703) 292-8143, email: dthornhi@nsf.gov
- Joaquin Martinez Martinez, NSF/GEO, telephone: (703) 292-8580, email: jmartine@nsf.gov
- Samuel M. Scheiner, Program Director, NSF/BIO, telephone: (703) 292-7175, email: sscheine@nsf.gov

Applicable Catalog of Federal Domestic Assistance (CFDA) Number(s):

- 10.310 --- USDA-NIFA Agriculture and Food Research Initiative
- 47.050 --- Geosciences
- 47.074 --- Biological Sciences
- 47.075 --- Social Behavioral and Economic Sciences
- 93.856 --- Microbiology and Infectious Diseases Research
- 93.859 --- National Institute of General Medical Sciences
- 93.989 --- John E. Fogarty International Center

Award Information

Anticipated Type of Award: Standard Grant or Continuing Grant

Estimated Number of Awards: 12

Anticipated Funding Amount: \$24,000,000



59 MDW/ST Summary of Funding Announcements for October 2020



in FY 2021, pending the availability of funds. That amount includes approximately \$11.0M from NSF for new standard or continuing awards, approximately \$7.5M from NIH for new or continuing awards, and \$5.5M from USDA for new awards. The expected funding from the UKRI for the UK component of the US-UK Collaborative Projects will be a maximum of £2M. The expected funding from the BSF for the Israeli component of the US-Israel Collaborative Projects will be a maximum of \$720,000. The expected funding from the NSFC for the Chinese component of the US-China Collaborative Projects will be a maximum of ¥9M.

Eligibility Information

Who May Submit Proposals:

The categories of proposers eligible to submit proposals to the National Science Foundation are identified in the *NSF Proposal & Award Policies & Procedures Guide* (PAPPG), Chapter I.E. Unaffiliated individuals are not eligible to submit proposals in response to this solicitation.

Who May Serve as PI:

There are no restrictions or limits.

Limit on Number of Proposals per Organization:

There are no restrictions or limits.

Limit on Number of Proposals per PI or Co-PI: 2

In a given year, an individual may participate as a PI, co-PI, or subaward lead on no more than **two** proposals submitted in response to this solicitation. **This limit does not include Research Coordination Networks (RCN) proposals.** In addition, an individual from Israel may participate in no more than **one** US-BSF proposal and an individual from China may participate in no more than **one** US-China proposal. Proposals in excess of the limit for any person will be returned without review in the reverse order received. Participating in a proposal as other senior personnel does not count in this limit. Changes in investigator roles post-submission to meet the eligibility limits will not be allowed. **It is the responsibility of the submitters to confirm that the entire team is within the eligibility guidelines.**

- **Continuously Open Announcements:**

Special Operations Forces (SOF) open Broad Area Announcement (BAA) for USSOCOM Biomedical Research Advisory Group (BRAG) to fund biomedical, human performance, and canine research to identify and develop techniques, knowledge products, and materials (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance. SOF medics place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. For more information:



59 MDW/ST Summary of Funding Announcements for October 2020



<https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH-USSOCOM>

The United States Army Medical Research and Development Command (USAMRDC) funds a broad range of extramural research programs. Awards are usually contracts, grants, or cooperative agreements. Research proposals can be submitted to the command through the USAMRMC Broad Agency Announcement (BAA), which is continuously open, or through special USAMRMC BAA Announcements, which are open for limited timeframes. Examples of programs with special announcements are the Breast Cancer Research Program, the Prostate Cancer Research Program, Gulf War Illness, and others. Additional information, the USAMRMC Broad Agency Announcement, and open special USAMRMC BAA Announcements can be obtained at <http://www.usamraa.army.mil/Pages/BAA.aspx>

USAMRMC also maintains a safe method for submitting new products and ideas for consideration: <https://mrmc-npi.amedd.army.mil/>; provides subject matter experts to assess products and ideas, evaluate their applicability to USAMRMC's mission, and provide feedback to the submitter for development and possibly funding.

711 HPW BAA: The Airman Readiness Medical Research (ARMR) Hybrid Broad Area Announcement (BAA) was just released to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to

ameliorate these stressors to optimize Airman health and performance. This BAA will remain open for seventy-two (72) months with Calls being released throughout the seventy-two (72) month period of performance. Link:

[https://beta.sam.gov/opp/31a536d407cd4d519fc89ffd3366cbb3/view?keywords=%20Airman%20Readiness%20Medical%20Research%20\(ARMR\)%22&sort=relevance&index=&is_active=true&page=1](https://beta.sam.gov/opp/31a536d407cd4d519fc89ffd3366cbb3/view?keywords=%20Airman%20Readiness%20Medical%20Research%20(ARMR)%22&sort=relevance&index=&is_active=true&page=1)

- **Additional Funding Sources Compiled the Henry Jackson Foundation.**
<https://www.hjf.org/funding-opportunities>



59 MDW/ST Summary of Funding Announcements for October 2020



Title	Opportunity Number	Sponsor	Closing Date
Strengthening Teamwork for Robust Operations in Novel Groups (STRONG)	W911NF-19-S-0001	US ARMY RESEARCH LABORATORY	2028-10-29
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	PA-20-135	NIH	2025-09-07
UNITED STATES MILITARY ACADEMY Broad Agency Announcement	W911NF-20-S-0008	DoD	2025-03-31
Fundamental Research to Counter Weapons of Mass Destruction	HDTRA1-14-24-FRCWMD-BAA	DEFENSE THREAT REDUCTION AGENCY	2024-09-30
Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)	PAR-20-179	NIH	2023-09-07
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical Research and Development	W81XWH-18-S-SOC1	DoD	2023-07-31
Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)	PAR-20-266	NIH	2023-06-19
Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)	PAR-20-282	NIH	2023-06-19
Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)	PAR-20-281	NIH	2023-06-19



59 MDW/ST Summary of Funding Announcements for October 2020



NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)	PAR-20-270	NIH	2023-05-12
Research Project Grant (Parent R01 Clinical Trial Required)	PA-20-183	NIH	2023-05-07
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	PAR-20-077	NIH	2023-05-07
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)	PAR-20-122	NIH	2023-05-07
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	PA-20-194	NIH	2023-05-07
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	PA-20-184	NIH	2023-05-07
Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)	PAR-20-232	NIH	2023-05-07
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	PA-20-195	NIH	2023-05-07
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	PA-20-200	NIH	2023-05-07



59 MDW/ST Summary of Funding Announcements for October 2020



NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	PA-20-185	NIH	2023-05-07
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)	PAR-20-154	NIH	2023-05-07
Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)	PAR-20-233	NIH	2023-05-07
Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	PAS-20-160	NIH	2023-05-07
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	PA-20-185	NIH	2023-05-07
Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)	RFA-HG-20-036	NIH	2023-03-13
Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)	PAR-20-103	NIH	2023-01-27
Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)	PAR-20-139	NIH	2023-01-14
Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)	PAR-19-389	NIH	2023-01-07
Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)	PAR-19-377	NIH	2023-01-07



59 MDW/ST Summary of Funding Announcements for October 2020



[NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 \(NCI Omnibus R03 Clinical Trial Optional\)](#)

PAR-20-052

NIH

2023-01-07

[Improving oral health and reducing disparities in adolescents \(R01 Clinical Trial Not Allowed\)](#)

PAR-20-058

NIH

2023-01-07

[NIBIB Trailblazer Award for New and Early Stage Investigators \(R21 Clinical Trial Optional\)](#)

PAR-20-084

NIH

2023-01-07

[Improving Quality of Care and Patient Outcomes During Care Transitions \(R01\)](#)

PA-20-068

NIH

2022-12-06

[Innovative Approaches to Science and Engineering Research on Brain Function](#)

NSF 20-609

NSF

2022-11-22

[DoD USAMRDC FY18-FY22 Broad Agency Announcement for Extramural Medical Research](#)

W81XWH18SBAA1 CDMRP

2022-09-30

[Single-Site Investigator-Initiated Clinical Trials \(R61/R33 Clinical Trial Required\)](#)

PAR-19-328

NIH

2022-09-08

[NIDA Program Project Grant Applications \(P01 Clinical Trial Optional\)](#)

PAR-19-345

NIH

2022-09-07

[Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes \(R01 Clinical Trial Not Allowed\)](#)

PAR-20-276

NIH

2022-09-07

[NIDCR Small Grant Program for New Investigators \(R03 Clinical Trial Not Allowed\)](#)

PAR-19-370

NIH

2022-09-07



59 MDW/ST Summary of Funding Announcements for October 2020



[NIAID Investigator Initiated Program Project Applications \(P01 Clinical Trial Not Allowed\)](#)

PAR-20-072

NIH

2022-09-07

[Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization \(R01 Clinical Trial Optional\)](#)

PAR-19-352

NIH

2022-09-07

[Cellular and Biochemical Engineering](#)

PD 20-1491

NSF

2022-09-01

[Biosensing](#)

PD 20-7909

NSF

2022-09-01

[Disability and Rehabilitation Engineering \(DARE\)](#)

PD 20-5342

NSF

2022-09-01

[Innovation for HIV Vaccine Discovery \(R01 Clinical Trial Not Allowed\)](#)

PAR-20-158

NIH

2022-07-28

[Surgical Disparities Research \(R01 - Clinical Trial Optional\)](#)

PAR-20-079

NIH

2022-07-05

[Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment \(R01 Clinical Trial Optional\)](#)

PAR-19-340

NIH

2022-06-08

[Disease Modifying Therapies for Chronic Lung Disease \(R61/R33 Clinical Trial Required\)](#)

RFA-HL-21-013

NIH

2022-06-01

[Neural Regulation of Cancer \(R21 Clinical Trial Not Allowed\)](#)

PAR-19-354

NIH

2022-05-27

[Focused Technology Research and Development \(R01 - Clinical Trial Not Allowed\)](#)

PAR-19-253

NIH

2022-05-07



59 MDW/ST Summary of Funding Announcements for October 2020



Limited Competition:

Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed)

PAR-19-234

NIH

2022-05-07

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)

PA-19-201

NIH

2022-05-07

Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed)

PAR-19-194

NIH

2022-05-07

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

PAR-19-315

NIH

2022-05-07

Biology of Bladder Cancer (R21 Clinical Trial Optional)

PAR-19-184

NIH

2022-05-07

Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior (R01 Clinical Trial Optional)

PAR-19-344

NIH

2022-03-10

Laboratories to Optimize Digital Health (R01 Clinical Trial Required)

RFA-MH-20-510

NIH

2022-03-02

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

PAR-19-325

NIH

2022-02-11

Advances in Patient Safety through Simulation Research (R18)

PA-16-420

NIH

2022-01-26

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements

PA-18-935

NIH

2022-01-24



59 MDW/ST Summary of Funding Announcements for October 2020



[\(Urgent Supplement - Clinical Trial Optional\)](#)

[Processing and Presentation of Non-Conventional MHC Ligands \(R21 Clinical Trial Not Allowed\)](#)

PA-19-066

NIH

2022-01-08

[Exploratory/Developmental Bioengineering Research Grants \(EBRG\) \(R21 Clinical Trial Optional\)](#)

PAR-19-150

NIH

2022-01-07

[Comparative Effectiveness Research in Clinical Neurosciences \(UG3/UH3 Clinical Trial Not Allowed\)](#)

PAR-19-171

NIH

2022-01-07

[Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain \(R21 Clinical Trial Optional\)](#)

PA-18-946

NIH

2022-01-07

[Biobehavioral Basis of Chronic Pain \(R01 Clinical Trial Optional\)](#)

PA-18-944

NIH

2022-01-07

[Exploratory/Developmental Bioengineering Research Grants \(EBRG\) \(R21 Clinical Trial Not Allowed\)](#)

PAR-19-149

NIH

2022-01-07

[Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development \(R01 Clinical Trial Not Allowed\)](#)

PA-19-065

NIH

2022-01-07

[Research on Chronic Overlapping Pain Conditions \(R21 Clinical Trial Not Allowed\)](#)

PA-18-939

NIH

2022-01-07

[Advancing Development of Rapid Fungal Diagnostics](#)

PA-19-081

NIH

2022-01-07



59 MDW/ST Summary of Funding Announcements for October 2020



[\(R21 Clinical Trial Not Allowed\)](#)

[Accelerating Malaria Vaccine Discovery \(R01 Clinical Trial Not Allowed\)](#)

PA-19-077

NIH

2022-01-07

[New Research Directions that Advance the NHLBI Strategic Vision Normal Biology \(R21 - Clinical Trial Not Allowed\)](#)

PA-19-049

NIH

2022-01-07

[Control of Sexually Transmitted Infections \(STIs\) Through a Comprehensive Understanding of the Natural History of Infection \(R01 Clinical Trial Not Allowed\)](#)

PA-19-096

NIH

2022-01-07

[Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain \(R01 Clinical Trial Optional\)](#)

PA-18-945

NIH

2022-01-07

[Sustained Release of Antivirals for Treatment or Prevention of HIV \(SRATP\) \(R01 Clinical Trial Not Allowed\)](#)

PAR-20-029

NIH

2022-01-07

[Research on Chronic Overlapping Pain Conditions \(R01 Clinical Trial Optional\)](#)

PA-18-937

NIH

2022-01-07

[Advancing Development of Rapid Fungal Diagnostics \(R01 Clinical Trial Not Allowed\)](#)

PA-19-080

NIH

2022-01-07

[Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research \(R21 Clinical Trial Not Allowed\)](#)

PA-19-068

NIH

2022-01-07

[Biobehavioral Basis of Chronic Pain \(R21 Clinical Trial Optional\)](#)

PA-18-943

NIH

2022-01-07



59 MDW/ST Summary of Funding Announcements for October 2020



Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)	RFA-HL-20-021	NIH	2021-12-21
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)	PAR-19-294	NIH	2021-11-12
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)	PAR-19-070	NIH	2021-11-12
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)	PAR-19-198	NIH	2021-11-08
Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)	PA-16-423	NIH	2021-10-30
BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Clinical Trial Required)	RFA-NS-19-001	NIH	2021-10-29
Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)	PAR-19-277	NIH	2021-10-08
NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)	PAR-19-137	NIH	2021-10-06
Cellular and Biochemical Engineering	PD-20-1491	NSF	2021-09-30
Countermeasures Against Chemical Threats (CounterACT): Optimization of	PAR-19-040	NIH	2021-09-14



59 MDW/ST Summary of Funding Announcements for October 2020



Therapeutic Lead Compounds (U01 Clinical Trial Optional)

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)

PAR-19-039

NIH

2021-
09-14

Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)

PA-18-857

NIH

2021-
09-08

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

PA-18-902

NIH

2021-
09-07

Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 - Clinical Trial Optional)

PA-18-838

NIH

2021-
09-07

Prevention Research in Mid- Life Adults (R21 Clinical Trial Optional)

PA-18-850

NIH

2021-
09-07

Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)

PA-18-859

NIH

2021-
09-07

Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)

PAR-18-844

NIH

2021-
09-07

Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active

PAR-18-890

NIH

2021-
09-07



59 MDW/ST Summary of Funding Announcements for October 2020



Cooperative Agreements (U01 Clinical Trial Not Allowed)

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)

PAS-18-915

NIH

2021-
09-07

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)

PA-18-784

NIH

2021-
09-07

Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)

PA-19-042

NIH

2021-
09-07

Advancing Research Needed to Develop a Universal Influenza Vaccine (R21 Clinical Trial Not Allowed)

PA-18-858

NIH

2021-
09-07

Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)

PA-18-856

NIH

2021-
09-07

Prevention Research in Mid- Life Adults (R01 Clinical Trial Optional)

PA-18-849

NIH

2021-
09-07

High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed)

PAR-18-929

NIH

2021-
09-07

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

PAR-18-892

NIH

2021-
09-07

Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)

PA-18-876

NIH

2021-
09-07



59 MDW/ST Summary of Funding Announcements for October 2020



BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)	RFA-MH-20-128	NIH	2021-09-02
Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed)	PAR-19-285	NIH	2021-08-20
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)	RFA-DA-21-019	NIH	2021-07-20
Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed)	PAR-18-867	NIH	2021-07-17
Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21)	PA-17-246	NIH	2021-07-16
Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)	RFA-HG-20-048	NIH	2021-07-08
Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)	PAR-18-868	NIH	2021-07-06
AHRQ Health Services Research Projects (R01)	PA-18-795	NIH	2021-07-05
Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care	RFA-MH-20-506	NIH	2021-07-01



59 MDW/ST Summary of Funding Announcements for October 2020



Settings (R34 Clinical Trial Required)

Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 Clinical Trial Not Allowed)

PAR-19-247 NIH 2021-06-18

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)

RFA-MH-20-350 NIH 2021-06-10

Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R01 Clinical Trial Not Allowed)

PAR-19-248 NIH 2021-06-10

Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)

PAR-20-133 NIH 2021-06-08

Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required)

PAR-20-134 NIH 2021-06-08

NIDCD Hearing Healthcare for Adults: Improving Access and Affordability (R21/R33 Clinical Trials Optional)

RFA-DC-19-001 NIH 2021-06-04



59 MDW/ST Summary of Funding Announcements for October 2020



The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)	PAR-18-830	NIH	2021-06-03
Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)	PAR-19-369	NIH	2021-05-07
NINDS Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)	PA-18-358	NIH	2021-05-07
Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R01 Clinical Trial Optional)	PA-18-493	NIH	2021-05-07
Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)	PAR-19-159	NIH	2021-05-07
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)	PAR-19-222	NIH	2021-05-07
Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)	PA-18-741	NIH	2021-05-07
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)	PA-18-677	NIH	2021-05-07
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention.	PA-18-738	NIH	2021-05-07



59 MDW/ST Summary of Funding Announcements for October 2020



[Treatment and Progression \(R01 Clinical Trial Optional\).](#)

[Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development \(R21 Clinical Trial Not Allowed\)](#)

PA-18-724

NIH

2021-05-07

[Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity \(R21 Clinical Trials Not Allowed\)](#)

PA-18-754

NIH

2021-05-07

[Innovation Grants to Nurture Initial Translational Efforts \(IGNITE\): Assay Development and Neurotherapeutic Agent Identification \(R61/R33 Clinical Trial Not Allowed\)](#)

PAR-18-762

NIH

2021-05-07

[Mechanisms, Models, Measurement, and Management in Pain Research \(R21 Clinical Trial Optional\)](#)

PA-18-159

NIH

2021-05-07

[Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer \(R21 Clinical Trial Optional\)](#)

PA-18-492

NIH

2021-05-07

[Mechanisms, Models, Measurement, and Management in Pain Research \(R01 Clinical Trial Optional\)](#)

PA-18-141

NIH

2021-05-07

[Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder \(R01 - Clinical Trial Optional\)](#)

PA-18-619

NIH

2021-05-07

[NINDS Exploratory Clinical Trials \(U01 - Clinical Trials Required\)](#)

PAR-18-420

NIH

2021-05-07



59 MDW/ST Summary of Funding Announcements for October 2020



[Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health \(R21 Clinical Trial Optional\)](#)

PA-18-723

NIH

2021-05-07

[Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity \(R01 Clinical Trial Optional\)](#)

PA-18-753

NIH

2021-05-07

[Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility \(R21 - Clinical Trial Not Allowed\)](#)

PA-18-678

NIH

2021-05-07

[Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression \(R21 Clinical Trial Optional\).](#)

PA-18-739

NIH

2021-05-07

[Generating New insights and Mechanistic Understanding of Antibiotic Resistance Development \(R01 Clinical Trial Not Allowed\)](#)

PA-18-725

NIH

2021-05-07

[Innovation Grants to Nurture Initial Translational Efforts \(IGNITE\): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies \(R61/R33 Clinical Trial Not Allowed\)](#)

PAR-18-761

NIH

2021-05-07

[Next Generation Multipurpose Prevention Technologies \(NGM\) \(R01 Clinical Trial Optional\)](#)

PAR-19-209

NIH

2021-05-06

[BRAIN Initiative: New Technologies and Novel Approaches for Large-Scale Recording and Modulation in](#)

RFA-NS-18-020

NIH

2021-05-04



59 MDW/ST Summary of Funding Announcements for October 2020



[the Nervous System \(R01 Clinical Trials Not Allowed\)](#)

Biological Technologies	HR 00 1120 S 0044	DARPA	2021- 04-22
---	----------------------	-------	----------------

[Opportunities for Collaborative Research at the NIH Clinical Center \(U01 Clinical Trial Optional\)](#)

PAR-18-951	NIH	2021- 04-15
------------	-----	----------------

[NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience \(D-SPAN\) Award \(F99/K00\)](#)

RFA-NS-19-011	NIH	2021- 04-15
---------------	-----	----------------

[PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications \(Parent SBIR \[R43/R44\] Clinical Trial Not Allowed\)](#)

PA-20-260	NIH	2021- 04-05
-----------	-----	----------------

[Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery \(R01 Basic Experimental Studies with Humans Required\)](#)

PAR-19-384	NIH	2021- 03-17
------------	-----	----------------

[Modular R01s in Cancer Control and Population Sciences \(R01 Clinical Trial Optional\)](#)

PAR-18-869	NIH	2021- 03-08
------------	-----	----------------

[NeuroNEXT Clinical Trials \(U01 - Clinical Trial Optional\)](#)

PAR-18-528	NIH	2021- 03-05
------------	-----	----------------

[BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data \(R01 Clinical Trial Not Allowed\)](#)

RFA-MH-19-147	NIH	2021- 03-04
---------------	-----	----------------

[Aerospace Medicine, Clinical Research, Human](#)

BAAAFRL- RQKHC-2016-0009	AFRL	2021- 03-01
-----------------------------	------	----------------



59 MDW/ST Summary of Funding Announcements for October 2020



Performance Research, and Expeditionary Medicine

Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed)

RFA-AI-20-057

NIH

2021-02-22

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional)

PAR-18-533

NIH

2021-02-22

BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required)

RFA-NS-18-021

NIH

2021-02-22

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

PAR-18-655

NIH

2021-02-18

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required)

RFA-MH-18-701

NIH

2021-02-18

Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)

RFA-CA-20-040

NIH

2021-02-17

Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)

PAR-18-742

NIH

2021-02-11

Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine

RFA-AI-20-055

NIH

2021-02-11



59 MDW/ST Summary of Funding Announcements for October 2020



[Strain Selection \(R01 Clinical Trial Not Allowed\)](#)

[Basic Research in Cancer Health Disparities \(R01 Clinical Trials Not Allowed\)](#)

PAR-18-654

NIH

2021-02-08

[A Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria \(U01 Clinical Trial Not Allowed\)](#)

RFA-AI-20-064

NIH

2021-02-08

[Utilizing Health Information Technology to Scale and Spread Successful Practice Models Using Patient-reported Outcomes \(R18\)](#)

PA-17-077

AHRQ

2021-01-25

[Administrative Supplements to Existing NIH Grants and Cooperative Agreements \(Parent Admin Supp - Clinical Trial Optional\)](#)

PA-18-591

NIH

2021-01-25

[NIAID Clinical Trial Implementation Cooperative Agreement \(U01 Clinical Trial Required\)](#)

PAR-18-633

NIH

2021-01-13

[Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2020](#)

PCORI Cycle 3 2020

PCORI

2021-01-12

[NIH Research Project Grant \(Parent R01 Clinical Trial Required\)](#)

PA-18-345

NIH

2021-01-08

[NIH Research Project Grant \(Parent R01 Clinical Trial Not Allowed\)](#)

PA-18-484

NIH

2021-01-08

[Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Postdoctoral Fellowship \(Parent F32\)](#)

PA-18-670

NIH

2021-01-08



59 MDW/ST Summary of Funding Announcements for October 2020



NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	PA-18-344	NIH	2021-01-08
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	PA-18-488	NIH	2021-01-08
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	PA-18-672	NIH	2021-01-08
High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)	PAS-18-698	NIH	2021-01-07
Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01-Clinical Trial Required)	PA-18-330	NIH	2021-01-07
Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional)	PA-18-615	NIH	2021-01-07
Research on Autism Spectrum (R01- Clinical Trial Optional)	PA-18-401	NIH	2021-01-07
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-Term Outcomes (R34-Clinical Trials Required)	PAR-18-431	NIH	2021-01-07
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 - Clinical Trials Required)	PAR-18-417	NIH	2021-01-07
Cancer Prevention and Control Clinical Trials Grant	PAR-18-559	NIH	2021-01-07



59 MDW/ST Summary of Funding Announcements for October 2020



Program (R01 Clinical Trial Required)

Basic and Translational Oral Health Research Related to HIV/AIDS (R21 Clinical Trial Not Allowed)

PA-18-695

NIH

2021-01-07

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)

PAR-18-554

NIH

2021-01-07

NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required

PAR-18-547

NIH

2021-01-07

Fundamental Science Research on Mind and Body Approaches (R21 - Clinical Trial Optional)

PA-18-322

NIH

2021-01-07

NIBIB Research Project Grant (R01 Clinical Trial Required)

PA-18-418

NIH

2021-01-07

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)

PA-18-348

NIH

2021-01-07

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)

PAR-18-684

NIH

2021-01-07

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

PAR-19-155

NIH

2021-01-07

NHLBI Program Project Applications (P01 - Clinical Trials Optional)

PAR-18-405

NIH

2021-01-07



59 MDW/ST Summary of Funding Announcements for October 2020



Promoting Research in Basic Neuroscience (R01)	PAS-18-483	NIH	2021-01-07
Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required)	PAR-18-430	NIH	2021-01-07
Innovative Mental Health Services Research Not Involving Clinical Trials (R01)	PAR-17-264	NIH	2021-01-07
NHLBI Clinical Trial Pilot Studies (R34 - Clinical Trial Optional)	PAR-18-463	NIH	2021-01-07
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)	PAR-18-560	NIH	2021-01-07
Basic and Translational Oral Health Research Related to HIV/AIDS (R01 Clinical Trial Not Allowed)	PA-18-699	NIH	2021-01-07
Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01) and Clinical Trial Optional	PAR-18-555	NIH	2021-01-07
Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed)	PA-18-525	NIH	2021-01-05
Enabling Discovery through GEnomic Tools (EDGE)	NSF 20-532	NSF	2020-12-31
DoD Pancreatic Cancer, Idea Development Award	W81XWH-20-PCARP-IDA	CDMRP	2020-12-10



59 MDW/ST Summary of Funding Announcements for October 2020



DoD Pancreatic Cancer, Translational Research Partnership Award	W81XWH-20-PCARP-TRPA	CDMRP	2020-12-10
Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01 - Clinical Trials Required)	RFA-HL-21-001	NIH	2020-12-09
DoD Duchenne Muscular Dystrophy, Idea Development Award	W81XWH-20-DMDRP-IDA	CDMRP	2020-12-07
DoD Duchenne Muscular Dystrophy, Translational Research Partnership Award	W81XWH-20-DMDRP-TRPA	CDMRP	2020-12-07
Secondary Data Analyses of the MSRC Common Data Elements(CDEs).	MSRC 2020	CDMRP	2020-12-06
DoD Scleroderma, Idea Development Award	W81XWH-20-SRP-IDA	CDMRP	2020-12-04
DoD Scleroderma, Translational Research Partnership Award	W81XWH-20-SRP-TRPA	CDMRP	2020-12-04
DoD Reconstructive Transplant, Clinical Network Award	W81XWH-20-RTRP-CNA	CDMRP	2020-12-03
Small Business Technology Transfer Program Phase I(STTR)	NSF-20-528	NSF	2020-12-03
DoD Combat Readiness, Rapid Development and Translational Research Award	W81XWH-20-S-CRRP	CDMRP	2020-12-03
DoD Rare Cancers, Resource and Community Development Award	W81XWH-20-RCRP-RCDA	CDMRP	2020-11-30
DoD Rare Cancers, Idea Development Award	W81XWH-20-RCRP-IDA	CDMRP	2020-11-30



59 MDW/ST Summary of Funding Announcements for October 2020



DoD Rare Cancers, Concept Award	W81XWH-20-RCRP-CA	CDMRP	2020-11-30
Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Basic Experimental Studies with Humans Required)	RFA-DE-21-001	NIH	2020-11-25
Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)	RFA-MH-19-242	NIH	2020-11-20
Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)	RFA-MH-19-240	NIH	2020-11-20
Vision Research Program, Focused Translational Team Science Award	W81XWH-20-VRP-FTTSA	CDMRP	2020-11-18
Vision Research Program, Translational Research Award	W81XWH-20-VRP-TRA	CDMRP	2020-11-18
FY20 AFRI Foundational and Applied Science	FY20 AFRI	USDA	2020-11-18
Vision Research Program, Investigator-Initiated Research Award	W81XWH-20-VRP-IIRA	CDMRP	2020-11-18
Hearing Health Care for Adults: Improving Access and Affordability (R21 Clinical Trial Optional)	PA-18-382	NIH	2020-11-16
Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)	PAR-18-747	NIH	2020-11-13
Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the	PAR-18-745	NIH	2020-11-13



59 MDW/ST Summary of Funding Announcements for October 2020



U.S. (R21 Clinical Trial Optional)

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (UG3/UH3 Clinical Trial Required)

RFA-TR-20-031 NIH 2020-11-12

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)

PAR-19-326 NIH 2020-11-12

DoD Reconstructive Transplant, Investigator-Initiated Research Award

W81XWH-20-RTRP-IIRA CDMRP 2020-11-12

BRAIN Initiative: Targeted BRAIN Circuits Projects-TargetedBCP (R01 Clinical Trial Not Allowed)

RFA-NS-18-030 NIH 2020-11-10

U.S. - India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed)

PAR-18-912 NIH 2020-11-09

Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)

PA-18-836 NIH 2020-11-07

DOD Chronic Pain Management, Translational Research Award

W81XWH-20-CPMRP-TRA CDMRP 2020-11-06

DOD Chronic Pain Management, Investigator-Initiated Research Award

W81XWH-20-CPMRP-IIRA CDMRP 2020-11-06

Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed)

RFA-HG-20-047 NIH 2020-11-04



59 MDW/ST Summary of Funding Announcements for October 2020



[Clinical Observational \(CO\) Studies in Musculoskeletal, Rheumatic, and Skin Diseases \(R01 Clinical Trial Not Allowed\)](#)

PAR-18-597

NIH

2020-11-03

[DoD Kidney Cancer, Clinical Research Nurse Development Award](#)

W81XWH-20-KCRP-CRNDA

CDMRP

2020-11-03

[Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases \(R21 Clinical Trial Required\)](#)

PAR-18-595

NIH

2020-11-03

[Bench Testing Therapeutic/Indication Pairing Strategies \(UG3/UH3\)](#)

PAR-17-465

NIH

2020-10-30

[Alkermes Pathways Research Awards](#)

Alkermes

2020-10-30

[BRAIN Initiative: New Concepts and Early - Stage Research for Large - Scale Recording and Modulation in the Nervous System \(R21\) \(Clinical Trial Not Allowed\)](#)

RFA-EY-18-001

NIH

2020-10-29